Stay updated with breaking news from Mike Sinclair. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ad Hoc Announcement Pursuant to Art. 53 LR Glenolden, PA and Geneva, Switzerland, September 22, 2021 (GLOBE NEWSWIRE) - The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder
Epeleuton decreases viral titres and SARS-CoV-2 RNA and histopathological damage in the upper and lower respiratory tract Afimmune, a clinical stage drug discovery company focused on the development
Addex Therapeutics Ltd: Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021 1 - Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Chief Executive Officer, Tim Dyer, will present at Access to Giving Virtual Conference at 9 AM ET on July 14, 2021. Mr. Dyer will give a corporate update, including an overview of recent advances in Addex's clinical trial program. The conference is free to all registrants. Registration Details Time: 9 a.m. ET Link: htt...
Addex Therapeutics Ltd: Addex, Stanford University and University of Copenhagen Publish mGlu2 Structure in Nature Using Addex Allosteric Modulators Data could enable acceleration of lead optimization using computer aided drug discovery tools Addex existing mGlu2 positive allosteric modulator, ADX71149, in clinical studies for epilepsy and mGlu2 negative allosteric modulators in preclinical development for neurocognitive disorders Ge 2 1 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and developme...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia ... Addex TherapeuticsJune 29, 2021 GMT Geneva, Switzerland, June 29, 2021 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that screening of patients has started for its pivotal Phase 2b/3 study with dipraglurant for dyskinesia associated with Parkinson’s disease (PD-LID). Dyskines...